Iterum Therapeutics shares rise 10.36% intraday after securing Medicare Part D rebate agreement and expanding Cencora distribution.

Iterum Therapeutics surged 10.36% intraday following a business update highlighting key market access and patent developments. The company secured a rebate agreement with a top-three Medicare Part D Pharmacy Benefit Manager, positioning ORLYNVAH™ for inclusion in Medicare formularies as early as Q1 2026. Additionally, reimbursement coverage expanded to nearly 25% of U.S. insured lives (60 million people), including Medicaid and VA programs. Distribution channels were expanded with Cencora (formerly AmerisourceBergen) now stocking ORLYNVAH™, alongside McKesson. The European Patent Office also signaled intent to grant a patent for a bilayer tablet formulation, extending exclusivity until 2039. These milestones—enhanced market access, broader distribution, and patent protection—collectively signaled progress in commercializing ORLYNVAH™, a novel antibiotic addressing multi-drug resistant infections, driving the intraday rally.